Aug 26 2024

DEA Schedules Public Hearing on Marijuana Rescheduling for December 2

The Drug Enforcement Administration (DEA) has announced a public hearing to address the agency’s proposal to reschedule marijuana from Schedule I, to Schedule III.

This hearing, set for December 2, will occur after the November elections.

“This is notice that the Drug Enforcement Administration will hold a hearing with respect to the proposed rescheduling of marijuana into schedule III of the Controlled Substances Act”, states the notice, which is currently unpublished in the Federal Register but will be officially published on Thursday. “The proposed rescheduling of marijuana was initially proposed in a Notice of Proposed Rulemaking published in the Federal Register on May 21, 2024.”
Continue reading

Aug 26 2024

NFL-Funded Study Explores Marijuana’s Potential in Sports

An NFL-funded study published in the journal Sports Medicine reveals the growing role of marijuana as a therapeutic tool for athletes, highlighting its potential to address issues like pain, anxiety and brain injuries, while also acknowledging the complications and lack of knowledge caused by strict laws and regulations.

(Photo credit: Getty Images).

“The increasing legalization of Cannabis sativa plant products has sparked growing interest in their therapeutic applications”, states the study’s abstract, which was also published by the US National Library of Medicine. “Prohibition laws established in 1937 hindered formal research on cannabis, a plant with cultural and medicinal roots dating back to 2700 BC in Chinese history. Despite regulatory hurdles, published research on cannabis has emerged; yet elite athletes remain an underrepresented population in these studies.”

It continues “Athletes, known for exploring diverse substances to optimize performance, are drawn to the potential benefits of cannabinoid therapy, with anecdotal reports suggesting positive effects on issues ranging from anxiety to brain injuries.”
Continue reading

Aug 26 2024

Republican Congressmember Predicts Marijuana Will be Rescheduled “Right Before the Election”

Congressmember Nancy Mace (R-SC) says she believes the Biden administration will finalize its marijuana rescheduling plan “right before the election”.

Congressmember Nancy Mace (R-SC).

Mace, who is the sponsor of the States Reform Act to protect state marijuana laws, discussed the political implications of cannabis and the likelihood of rescheduling during an interview with The Dales Report. Mace’s remarks are consistent with those of a DEA official who said that a final rescheduling order is likely to be issued before October.

When asked if she believes Trump will endorse marijuana reform following his recent comments that he’s beginning to “agree a lot more” that marijuana should be legalized, Mace expressed uncertainty. However, she pointed out his prior support for medical cannabis and emphasized her desire to hear him back rescheduling, noting the “statistically significant number of Republicans” who favor such policies.
Continue reading

Aug 26 2024

Study: CBD May Protect Against Sepsis-Induced Renal Damage

The results of a new study published in the peer-reviewed journal Naunyn-Schmiedeberg’s Archives of Pharmacology “underscores CBD as a promising protective agent against sepsis-induced renal damage.”

The research, conducted by teams from Suleyman Demirel University and Burdur Mehmet Akif Ersoy University in Turkey, explored how CBD could mitigate the harmful effects of lipopolysaccharide (LPS)-induced kidney injury in Wistar Albino rats.

Sepsis, a severe and life-threatening condition, often leads to significant renal damage, posing a major challenge in clinical settings. The study investigated the protective effects of CBD, known for its antioxidant and anti-inflammatory properties, in a controlled laboratory setting.
Continue reading

Aug 26 2024

Study Finds THC Amplifies CBD’s Role in Improving Schizophrenia Symptoms

A new study published in the journal BMJ Mental Health reveals promising insights into the effects of cannabidiol (CBD) on key biomarkers associated with schizophrenia.

Conducted by researchers from Germany’s Central Institute of Mental Health, Goethe University Frankfurt, the University of Goettingen, and Australia’s University of Sydney, the randomized clinical trial explored how varying doses of CBD—both alone and in combination with delta-9-tetrahydrocannabinol (Δ9-THC)—impact endocannabinoid levels in healthy volunteers.

“The mental health benefits of cannabidiol (CBD) are promising but can be inconsistent, in part due to challenges in defining an individual’s effective dosage,” states the study’s abstract. “In schizophrenia, alterations in anandamide (AEA) concentrations, an endocannabinoid (eCB) agonist of the eCB system, reflect positively on treatment with CBD. Here, we expanded this assessment to include eCBs alongside AEA congeners, comparing phytocannabinoids and dosage in a clinical setting.”
Continue reading

Aug 26 2024

Arkansas: $22.9 Million in Medical Marijuana Sold in July, Over $150 Million Year-to-Date

Medical marijuana patients in Arkansas purchased nearly $23 million worth of marijuana and marijuana products in July.

According to the Arkansas Department of Finance and Administration (DFA), there was $22.9 million in marijuana sold legally in July via 37 medical marijuana dispensaries. This is nearly identical to the $22.8 million sold in April and the $22.9 million sold in May, and an uptick from the $21.7 million sold in June.

The year-to-date total for medical marijuana sales in Arkansas is now $158 million, putting the stop on track to easily top a quarter of a billion dollars by the end of the year. In total, there are around 105,000 medical marijuana patients in the state.
Continue reading

Aug 26 2024

New York Office of Cannabis Management Acting Director Says They Won’t Process 2023 Marijuana Applications Until 2025

The head of the New York Office of Cannabis Management (OCM) says that they don’t plan to finish reviewing 2023 applications for those wanting to enter the recreational marijuana market until sometime in 2025.

Felicia Reid, acting director of the OCM, told Spectrum News 1 that there are still 600 applications pending for marijuana retailers and microbusiness that were filed in November 2023. Reid says the review of these applications will continue until “early next year”.

Reid says applicants from December’s marijuana cultivation queue will wait even longer. Reid says they will be reviewed “on a rolling basis” after completion of the November queue.
Continue reading

Aug 26 2024

Rhode Island to Open First State-Sanctioned Overdose Prevention Center in the U.S. This Fall

Rhode Island is set to open its first state-sanctioned overdose prevention center (OPC) this fall, according to a report by Filter Mag.

The center, operated by Project Weber/RENEW, will be located at 45 Willard Ave in Providence and is expected to provide vital resources and support to individuals who use and are addicted to illicit drugs like heroin.

“We plan to have the overdose prevention center open in the fall”, said Claire Macon in Providence, Rhode Island, who is the outlets Overdose Prevention Center Manager.
Continue reading

Aug 26 2024

An Updated List of Every Marijuana Bill Currently Active in the US Congress (Over 20)

Here’s a current and updated list of all marijuana-related bills actively being considered in the United States Congress.

Although marijuana is legal for medical use in 38 states, and for recreational use in 24, it remains entirely illegal on the federal level. A bevy of federal legislation to change that is currently alive in the US Congress, although only a few have a legitimate chance of being passed into law in the near future.

Under congressional rules, any marijuana bill introduced before January 2023 has already been rendered inactive. Bills introduced on or after January 2023 will remain active until the end of the current legislative session in January 2025 unless they are enacted into law. Lawmakers may choose to reintroduce any inactive bills in future sessions.
Continue reading

Aug 26 2024

California Funds Project to Protect “Legacy Cannabis Culture and Genetics”

A group of academic researchers, scientists, and community-based organizations today announced the launch of a first-of-its-kind, multidisciplinary, community-based participatory research (CBPR) study for cannabis agriculture.

Funded by a $2.7 million grant from the California Department of Cannabis Control, the project incorporates public education and CBPR to implement the standard methods and systems used across agriculture to define, document, and legally protect as intellectual property the individual and collective genetic resources of legacy cannabis breeders and legacy cannabis cultivation communities.

“The CBPR model is a partnership approach to research that equitably involves community members, organizational representatives, and academic researchers in all aspects of the research process,” explains UC Berkeley historian Dr. Todd Holmes, one of the researchers on the project. “For a historic project like this, it’s absolutely vital that the community is a partner in the design, implementation and analysis of the research.”
Continue reading